A detailed history of Great Diamond Partners, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Great Diamond Partners, LLC holds 1,709 shares of VRTX stock, worth $810,339. This represents 0.19% of its overall portfolio holdings.

Number of Shares
1,709
Previous 1,743 1.95%
Holding current value
$810,339
Previous $728,000 10.03%
% of portfolio
0.19%
Previous 0.17%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$392.81 - $485.53 $13,355 - $16,508
-34 Reduced 1.95%
1,709 $801,000
Q1 2024

May 08, 2024

SELL
$407.69 - $446.08 $6,523 - $7,137
-16 Reduced 0.91%
1,743 $728,000
Q4 2023

Feb 07, 2024

BUY
$343.0 - $410.68 $7,203 - $8,624
21 Added 1.21%
1,759 $715,000
Q3 2023

Oct 19, 2023

BUY
$338.18 - $362.46 $338 - $362
1 Added 0.06%
1,738 $604,000
Q2 2023

Jul 17, 2023

BUY
$314.42 - $351.91 $43,704 - $48,915
139 Added 8.7%
1,737 $611,000
Q1 2023

May 04, 2023

SELL
$283.23 - $323.1 $57,495 - $65,589
-203 Reduced 11.27%
1,598 $503,000
Q4 2022

Feb 01, 2023

SELL
$285.76 - $321.48 $33,148 - $37,291
-116 Reduced 6.05%
1,801 $520,000
Q3 2022

Oct 24, 2022

SELL
$273.83 - $305.53 $22,727 - $25,358
-83 Reduced 4.15%
1,917 $555,000
Q2 2022

Jul 26, 2022

SELL
$234.96 - $292.55 $113,485 - $141,301
-483 Reduced 19.45%
2,000 $563,000
Q1 2022

May 05, 2022

SELL
$221.42 - $260.97 $33,877 - $39,928
-153 Reduced 5.8%
2,483 $647,000
Q4 2021

Jan 26, 2022

SELL
$177.01 - $223.45 $6,726 - $8,491
-38 Reduced 1.42%
2,636 $578,000
Q3 2021

Oct 21, 2021

BUY
$181.39 - $202.99 $485,036 - $542,795
2,674 New
2,674 $485,000
Q1 2020

May 01, 2020

SELL
$199.77 - $247.81 $6,792 - $8,425
-34 Closed
0 $0
Q4 2019

Feb 07, 2020

BUY
$166.71 - $223.91 $5,668 - $7,612
34 New
34 $7,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Great Diamond Partners, LLC Portfolio

Follow Great Diamond Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Diamond Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Diamond Partners, LLC with notifications on news.